(Q46107985)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

title

Mutations in the Kinase Domain of the HER2/ERBB2 Gene Identified in a Wide Variety of Human Cancers (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

Wenhsiang Wen

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Wangjuh Sting Chen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Nick Xiao

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Ryan Bender

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Anatole Ghazalpour

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Zheng Tan

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Jeffrey Swensen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sherri Z Millis

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Gargi Basu

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Zoran Gatalica

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Michael F Press

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

1 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

The Journal of Molecular Diagnostics

23 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

page(s)

487-495

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas.

23 February 2020

cites work

1 reference

12 December 2020

Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

1 reference

12 December 2020

Trastuzumab emtansine for HER2-positive advanced breast cancer

1 reference

12 December 2020

HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas

1 reference

12 December 2020

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma

1 reference

12 December 2020

Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.

1 reference

12 December 2020

Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials

1 reference

12 December 2020

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

12 December 2020

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment

1 reference

12 December 2020

Diverse somatic mutation patterns and pathway alterations in human cancers

1 reference

12 December 2020

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

12 December 2020

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

1 reference

12 December 2020

HER2 mutations in non-small-cell lung cancer can be continually targeted.

1 reference

12 December 2020

Landscape of genomic alterations in cervical carcinomas

1 reference

12 December 2020

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

12 December 2020

Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival

1 reference

12 December 2020

Comprehensive molecular characterization of human colon and rectal cancer

1 reference

12 December 2020

Comprehensive molecular characterization of urothelial bladder carcinoma

1 reference

12 December 2020

The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.

1 reference

12 December 2020

Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.

1 reference

12 December 2020

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

1 reference

12 December 2020

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

1 reference

12 December 2020

Activating HER2 mutations in HER2 gene amplification negative breast cancer

1 reference

12 December 2020

Integrated genomic analyses of ovarian carcinoma

1 reference

12 December 2020

Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial

1 reference

12 December 2020

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

12 December 2020

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

1 reference

12 December 2020

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

1 reference

12 December 2020

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

1 reference

12 December 2020

Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas.

1 reference

12 December 2020

Heterogeneity of erbB-2 gene amplification in bladder cancer

1 reference

12 December 2020

Somatic mutations affect key pathways in lung adenocarcinoma

1 reference

12 December 2020

Relapsed classic E-cadherin (CDH1)-mutated invasive lobular breast cancer shows a high frequency of HER2 (ERBB2) gene mutations

1 reference

12 December 2020

Comprehensive molecular portraits of human breast tumours

1 reference

12 December 2020

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

12 December 2020

The landscape of cancer genes and mutational processes in breast cancer

1 reference

12 December 2020

HER-2 and TOP2A coamplification in urinary bladder cancer

1 reference

12 December 2020

Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives

1 reference

12 December 2020

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

1 reference

12 December 2020

Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis

1 reference

12 December 2020

Treatment of metastatic extramammary Paget's disease associated with adnexal adenocarcinoma, with anti-HER2 drugs based on genomic alteration ERBB2 S310F

1 reference

12 December 2020

Sequence analysis of mutations and translocations across breast cancer subtypes

1 reference

12 December 2020

A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma

1 reference

12 December 2020

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update

1 reference

12 December 2020

Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism

1 reference

12 December 2020

Lung cancer: intragenic ERBB2 kinase mutations in tumours

1 reference

12 December 2020

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

12 December 2020

A census of human cancer genes

1 reference

12 December 2020

10.1016/J.JMOLDX.2015.04.003

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26320869%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

PubMed publication ID

26320869

1 reference